Edwards Lifesciences quarterly sales jump on robust demand for heart devices

Edwards Lifesciences Corp on Wednesday reported a 12% rise in third-quarter sales, helped by strong demand for the company's artificial heart valves and other devices. Medical device makers are lately benefiting from a rebound in non-urgent procedures that were otherwise delayed by pandemic-induced curbs, along with the easing of staffing pressure in the United States. Sales of Edward's transcatheter aortic valve replacement (TAVR), a device used to perform minimally invasive surgery for people with heart valve disease, rose 11% to $960.9 million in the third quarter.